The largest trial to date of a headset device that delivers flickering light and sound in an attempt to slow the progression of Alzheimer’s has delivered mixed results.
The device is based on the theory that audiovisual stimulation can evoke brainwave responses that might help preserve neurological function and clear waste from the brain. The idea is appealing because, if such a treatment works, it could provide an accessible non-drug alternative to Alzheimer’s medications that are expensive and carry significant safety risks.
Results of the study of the device, presented on Monday evening at a major Alzheimer’s conference, showed that the 12-month trial involving participants with mild to moderate Alzheimer’s did not achieve its primary goal. The overall group of patients who used the audiovisual device did not experience slower cognitive decline than those who used an inactive placebo device called a sham.
Patients with moderate Alzheimer’s showed no benefit at all from the system, called Spectris, according to data provided by the company, Cognito Therapeutics, which sponsored the trial. But for patients with mild Alzheimer’s, data generally suggested they could experience slower decline with the device, particularly if they used it nearly every day for close to the recommended 60 minutes.
Based on that, Cognito’s chief executive, Christian Howell, said the company planned to seek Food and Drug Administration approval.
“The signal we found in the mild population is really incredible,” Mr. Howell said in an interview. He attributed the trial’s failure to meet its primary goal to “the lack of treatment effect” in patients with moderate Alzheimer’s, but said that for mildly impaired patients, “there is a very clear path for us to the F.D.A.”
Some Alzheimer’s experts disagreed with that interpretation. They said more research was needed because they did not consider the results convincing enough to suggest a successful treatment for mildly impaired patients.
“Unfortunately, this is a negative trial and can only suggest that a new trial be performed in the mild Alzheimer’s group,” said Dr. Lon Schneider, who directs the California Alzheimer’s Disease Center at the University of Southern California.
In the trial, about half of the 663 participants were randomly assigned to receive the active device, designed to stimulate gamma waves in the brain to a frequency of 40 cycles per second (or 40 Hz). The other participants received a sham device.
Results for the overall population of participants, presented at the Clinical Trials on Alzheimer’s Disease conference in Boston, showed that after 12 months, those who received the active device declined by an average of 8.97 points on the 108-point primary scale used in the study, which combined measures of cognition and ability to perform daily activities. Participants who received the inactive device declined by an average of 8.82 points — showing no significant difference between the active and inactive treatment. The results have not yet been peer-reviewed or published in a journal.
Among patients considered moderately impaired, those who used the active device declined an average of 4.38 points, or 36 percent more than those who used the sham device.
Among mildly impaired patients, results trended in the opposite direction, with those using the active device declining an average of three points, or 42 percent slower than those who received the sham device.
The overall results for both moderate and mild groups did not meet the statistically significant threshold that scientists consider necessary for reliable findings.
Fewer than half the participants used their devices enough to be following the trial’s optimal protocol: at least 50 minutes per hourlong session, at least five days a week, for at least six months of the yearlong study.
But mildly impaired patients who followed that protocol did show statistically significant benefit from the active device, the study reported. Those 88 patients declined an average of five points, or 73 percent slower than the 81 patients who used the sham device according to the protocol.
Dr. Scott Small, director of the Alzheimer’s Disease Research Center at Columbia University, said the results of the overall trial were “disappointing,” especially since “the promise that a non-pharmacological intervention, one that can be potentially widely available, was met with high enthusiasm.”
Some experts said the countervailing results for mild and moderate patients made it harder to identify a clear pattern of benefit. Dr. Schneider said it was surprising “that one subgroup would benefit and the other would worsen, almost as mirror images of each other.”
He added: “Perhaps this could be useful in more mildly impaired people. However, another study has to be done to show that.”
Laura Nisenbaum, executive director of the Alzheimer’s Drug Discovery Foundation, a funder of Cognito, said the foundation had been “very intrigued by the mechanism because this is taking a very different approach.”
But she said she needed to see more data “to truly understand how robust, if any, signal they have.”
Dr. Nisenbaum said that, “if this were a drug, this essentially would not support submission for approval” because, for medication trials, if the primary goal is not met, “you do not advance to go.”
Cognito officials said they expected the F.D.A. to apply a different standard to a device like Spectris.
“For the first time, a medical device is coming into the world of Alzheimer’s, and that means that the F.D.A. process is just very different,” Mr. Howell said.
For example, said Dr. Robbert Zusterzeel, the company’s chief clinical and regulatory officer, while drug trials of this size would be considered small, the study is large for device trials. He said he believed the F.D.A. would welcome the fact that Spectris could be used at home without serious safety risks.
The theory behind the device is that gamma waves in the brain relate to cognitive processes like attention and memory. In Alzheimer’s, neuronal communication is disrupted, and gamma activity is often reduced.
Research in animals led by two Massachusetts Institute of Technology scientists, Li-Huei Tsai and Edward Boyden, who also co-founded Cognito, has found beneficial effects from using flickering light and sound to evoke gamma oscillations at a frequency of 40 Hz.
“You can think of it like a carwash, so it can clear a lot of the metabolic waste in the brain,” Dr. Tsai, director of the M.I.T. Picower Institute for Learning and Memory, said, adding that it also “increases synaptic plasticity and has this direct protective effect on neurons.”
“In the early days, we got a lot of criticism” from other scientists, she said. “People would be saying ‘Oh, this is like a fairy tale. You just use this very simple, straightforward light and sound stimulation, and it’s just too easy.’”
She said criticism lessened as she and others conducted more research. She said she was not directly involved in the Cognito trial, but believed it showed that mild Alzheimer’s patients could benefit and that regular device users “get the best treatment effect.”
Dr. Small said one important unanswered question was whether participants showed favorable changes in their levels of Alzheimer’s-related proteins — an indicator of whether or not the device could slow the disease process. Cognito said it expected to analyze that and other data in the coming months.
Cognito connected The New York Times to a trial participant with mild Alzheimer’s who received the active intervention.
The patient, Mireya Miranda, 78, of Miami, said she wore the headset daily, even taking it on a trip to Turkey. She said the sound through the headphones resembled staticky rain and what she saw in the glasses resembled a snowy television screen.
Her husband, Alberto, said his wife was very dedicated, but “it was an inconvenience.” Asked if the device seemed to slow her decline, he said, “I didn’t notice any difference.”
Ms. Miranda said she was now participating in another Alzheimer’s trial, involving infusions of an experimental drug. Asked if she would use the headset again if it became available, she replied, “If I have to do it again, I won’t.” She added, “I will not use it again because that hour seemed like three hours.”
In an interview also arranged by Cognito, Ms. Miranda’s neurologist, Dr. Andrew Lerman, an investigator in the trial, said Ms. Miranda was “very motivated” and consistently used the device. He said that gauging whether it helped her was challenging because Alzheimer’s trajectories vary widely, but that his staff believed she would have declined more without it.
He said some of his patients quit the trial. Some found the device “agitating to wear” or “just didn’t like having something on their face,” he said. But some patients enjoyed the experience, he said, and some are ineligible for Alzheimer’s drugs or like “the idea of a therapy where they don’t need to take another pill.”
